Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

491
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
491
Pharmacodynamic Models: Emax Drug–Concentration Effect Model01:18

Pharmacodynamic Models: Emax Drug–Concentration Effect Model

245
The Emax drug-concentration effect model is central to pharmacodynamics in drug discovery and development. This model is predicated on the receptor occupancy theory, which posits that the effect of a drug is directly related to the number of receptors occupied by the drug and the resultant complex formation.The model describes the reversible interaction between a drug (C) and a receptor (R) to form a drug-receptor complex (RC). The kinetics of this interaction are quantified by an equation that...
245
Pharmacodynamic Models: Linear Concentration–Effect Model01:15

Pharmacodynamic Models: Linear Concentration–Effect Model

91
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing...
91
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

121
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
121
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

157
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
157
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model01:14

Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

149
The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A...
149

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Leveraging training expertise to build capacity in computational personalised medicine.

Bioinformatics advances·2026
Same author

Deep representation learning for temporal inference in cancer omics: a systematic literature review.

Briefings in bioinformatics·2026
Same author

Airway organoids reveal patterns of influenza A tropism and adaptation in wildlife species.

Emerging microbes & infections·2026
Same author

Sex-specific transcriptome similarity networks elucidate comorbidity relationships.

Communications medicine·2025
Same author

Antidepressant and Antipsychotic Drug Use and Cancer Risk: Protocol for an Overview of Systematic Reviews and Meta-Analyses.

JMIR research protocols·2025
Same author

Constraint based modeling of drug induced metabolic changes in a cancer cell line.

NPJ systems biology and applications·2025

Related Experiment Video

Updated: May 5, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.2K

Experimentally calibrated multiscale model predicts schedule dependent drug combination effects.

Othmane Hayoun-Mya1,2, Arnau Montagud1,3, Alfonso Valencia1,4

  • 1Barcelona Supercomputing Center (BSC-CNS), 1-3 Plaça Eusebi Güell, 08034, Barcelona, Spain.

NPJ Systems Biology and Applications
|March 3, 2026
PubMed
Summary

This study introduces a multiscale model to predict drug combination effects by integrating molecular, cellular, and tissue dynamics. The model accurately forecasts outcomes, offering insights into optimizing combination therapy schedules for enhanced efficacy.

More Related Videos

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.5K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

21.0K

Related Experiment Videos

Last Updated: May 5, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.2K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.5K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

21.0K

Area of Science:

  • Computational Biology
  • Pharmacology
  • Systems Biology

Background:

  • Therapeutic synergy depends on complex interactions across molecular, cellular, and tissue levels.
  • Predicting drug combination effects requires integrating these diverse biological scales.
  • Current models often lack the multiscale integration needed for accurate prediction.

Purpose of the Study:

  • To develop and validate a multiscale computational model for predicting schedule-dependent drug combination effects.
  • To investigate the mechanistic insights governing drug synergy across different biological scales.
  • To establish a platform for in silico optimization of drug scheduling and combination strategies.

Main Methods:

  • Developed a multiscale model integrating molecular drug action, intracellular signaling, and tissue transport dynamics.
  • Calibrated the model using single-drug growth curves in the AGS cell line.
  • Validated the model's predictive accuracy for population-level outcomes of drug combinations.

Main Results:

  • The multiscale model accurately predicted drug combination effects without combination-specific training.
  • Cross-scale analysis revealed that pharmacokinetics influence molecular target engagement and cell-fate decisions.
  • Simulations predicted that inhibiting the PI3K/AKT axis before MEK is a more effective therapeutic schedule.

Conclusions:

  • The developed framework provides mechanistic, multiscale insights into drug combination logic.
  • This computational platform enables systematic in silico exploration of drug diffusion and dosing schedules.
  • The approach generates translationally relevant hypotheses for optimizing combination therapies.